Authors’ Disclosures
ONCOLOGY
S. Yadavilli reports employee and shareholder of GlaxoSmithKline. J.D. Waight reports employee and shareholder of GlaxoSmithKline. S. Brett is a former employee of and holds stocks/shares in GSK. C. Ellis reports GlaxoSmithKline employee and shareholder. D.C. Turner reports other from GSK during the conduct of the study; other from Genentech outside the submitted work. R. Gagnon reports personal fees from GSK outside the submitted work. S. Grant is an employee of GSK and has shares/stocks in GSK. Fishawack Health was contracted to facilitate article drafting and submission. M.P. DeYoung reports other from GSK during the conduct of the study; other from GSK outside the submitted work; and employee of GSK and shareholder. M. Chisamore reports other from Merck & Co outside the submitted work. R. Biddlecombe is an employee of GSK, has shares in GSK. R. Srinivasan reports employee and shareholder of GlaxoSmithKline. M. Maio reports other from ROCHE, BMS, MSD, Merck, AstraZeneca, IONTURA, Sciclone, Novartis, GSK, Sanofi, Eli Lilly, Pierre Fabre, Incyte, Alfasigma, and Amgen during the conduct of the study. D. Rischin reports grants from GSK during the conduct of the study; grants from MSD, BMS, Roche, Regeneron, ALX Oncology, and Decibel Therapeutics outside the submitted work. D. Olive reports grants from CRCM during the conduct of the study. E. Paul was an employee of GSK. E. Paul has since retired. P.A. Mayes reports other from Glaxosmithkline outside the submitted work; in addition, P.A. Mayes has a patent to Agonistic ICOS binding proteins pending. A. Hoos reports other from GSK during the conduct of the study; other from GSK outside the submitted work; in addition, A. Hoos has a patent to GSK issued. M. Ballas reports employeed at the time of this work by GSK. No disclosures were reported by the other authors.